Summary Summary The place of repetitive
The place of repetitive transcranial magnetic stimulation (rTMS) transcranial magnetic stimulation (rTMS) in the treatment of depression remains in the treatment of depression remains unclear.In this sham-controlled study we unclear.In this sham-controlled study we determined the efficacy and acceptability determined the efficacy and acceptability of fast, leftfrontalrTMS giventhree times a of fast, leftfrontalrTMS giventhree times a week over 4^6 weeks to 29 patients with week over 4^6 weeks to 29 patients with depression (79% treatment-resistant). depression (79% treatment-resistant). The procedure was generally well The procedure was generally well tolerated and more effective than sham tolerated and more effective than sham treatment (55 treatment (55 v. v. 7% responding, 7% responding, P P5 50.05), 0.05), with improvement maintained to12 with improvement maintained to12 weeks.This therapy could be a useful weeks.This therapy could be a useful addition to available treatments but addition to available treatments but further research is needed to determine further research is needed to determine the optimum treatment parameters. the optimum treatment parameters.
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Approximately a third of people treated for Approximately a third of people treated for depression fail to respond to initial treatdepression fail to respond to initial treatment and in 10-15% of cases the disorder ment and in 10-15% of cases the disorder is refractory to multiple treatments is refractory to multiple treatments (Anderson (Anderson et al et al, 2000) . The usefulness of , 2000) . The usefulness of repetitive transcranial magnetic stimulation repetitive transcranial magnetic stimulation (rTMS) is not clear because optimal treat-(rTMS) is not clear because optimal treatment parameters are unknown and studies ment parameters are unknown and studies have been small, of short duration and have have been small, of short duration and have used different methods (Loo & Mitchell, used different methods (Loo & Mitchell, 2005) . We investigated the antidepressant 2005). We investigated the antidepressant efficacy of rTMS in a clinically efficacy of rTMS in a clinically practical practical protocol in patients with depression. protocol in patients with depression.
METHOD METHOD
We recruited out-patients aged over 17 years We recruited out-patients aged over 17 years with a with a DSM-IV major depressive episode DSM-IV major depressive episode (American (American Psychiatric Association, 1994) , Psychiatric Association, 1994), diagnosed using the Mini International diagnosed using the Mini International Neuropsychiatric Interview (Lecrubier Neuropsychiatric Interview (Lecrubier et al et al, , 1997) , who were poorly responsive to -or 1997), who were poorly responsive to -or choosing not to take -antidepressant drugs. choosing not to take -antidepressant drugs. Exclusion criteria were safety considerExclusion criteria were safety considerations (e.g. suicidality, contraindications to ations (e.g. suicidality, contraindications to TMS), organic brain disorder, non-affective TMS), organic brain disorder, non-affective psychosis or current alcohol/drug misuse psychosis or current alcohol/drug misuse or dependence (by DSM-IV criteria). The or dependence (by DSM-IV criteria). The study was approved by the local research study was approved by the local research ethics committee and all participants gave ethics committee and all participants gave written informed consent. written informed consent.
After determination of motor threshold, After determination of motor threshold, patients were randomised (sealed envelope) patients were randomised (sealed envelope) to active or sham treatment stratified by to active or sham treatment stratified by degree of treatment resistance (fewer than degree of treatment resistance (fewer than two two v.
v. two or more antidepressant trials two or more antidepressant trials equivalent to imipramine 150 mg). Treatequivalent to imipramine 150 mg). Treatment was thrice weekly for 4 weeks, exment was thrice weekly for 4 weeks, extended for 2 more weeks in partial tended for 2 more weeks in partial responders. Medication at entry continued responders. Medication at entry continued unchanged through the trial. Assessments unchanged through the trial. Assessments were made before and 2, 4, 6 and 12 weeks were made before and 2, 4, 6 and 12 weeks after the start of treatment with patients after the start of treatment with patients and assessors unaware of treatment allocaand assessors unaware of treatment allocation. Assessments were the Mongomerytion. Assessments were the MongomeryAsberg Depression Rating Scale (MADRS; Å sberg Depression Rating Scale (MADRS; Montgomery & Asberg, 1979) , the Clinical Montgomery & Å sberg, 1979), the Clinical Global Impression Severity and ImproveGlobal Impression Severity and Improvement scales (CGI-S, CGI-I; Guy, 1976), ment scales (CGI-S, CGI-I; Guy, 1976), the Global Assessment of Functioning the Global Assessment of Functioning (GAF; American Psychiatric Association, (GAF; American Psychiatric Association, 1994) , and the self-rated Hospital Anxiety 1994), and the self-rated Hospital Anxiety and Depression scale (HAD; Zigmond & and Depression scale (HAD; Zigmond & Snaith, 1983) . Adverse effects were deterSnaith, 1983). Adverse effects were determined by open questions and a checklist. mined by open questions and a checklist.
Treatment using a Magstim Super Rapid Treatment using a Magstim Super Rapid (Magstim, Whitland, UK) was given using a (Magstim, Whitland, UK) was given using a figure-of-eight and matching sham coil. After figure-of-eight and matching sham coil. After determination of the motor threshold (the determination of the motor threshold (the minimum setting to stimulate the right first minimum setting to stimulate the right first abductor pollicis brevis muscle), treatment abductor pollicis brevis muscle), treatment sessions consisted of 1000 stimulations at sessions consisted of 1000 stimulations at 10 Hz in 20 trains each separated by 30 s at 10 Hz in 20 trains each separated by 30 s at 110% of motor threshold over the left dorso-110% of motor threshold over the left dorsolateral prefrontal cortex (5 cm anterior to the lateral prefrontal cortex (5 cm anterior to the motor threshold point). motor threshold point).
The primary outcome measures were The primary outcome measures were MADRS score and HAD depression scores MADRS score and HAD depression scores at treatment end-point given at least one at treatment end-point given at least one post-baseline assessment (last observation post-baseline assessment (last observation carried forward; LOCF). Secondary outcarried forward; LOCF). Secondary outcome measures were other rating scale come measures were other rating scale scores and responder status at treatment scores and responder status at treatment end-point (LOCF), scores at 12 weeks end-point (LOCF), scores at 12 weeks (LOCF and completers) and treatment (LOCF and completers) and treatment withdrawal. Response was defined as a rewithdrawal. Response was defined as a reduction of at least 50% in MADRS score duction of at least 50% in MADRS score plus a CGI-I rating of much or very much plus a CGI-I rating of much or very much improved. Partial response at 4 weeks was improved. Partial response at 4 weeks was defined as 25-49% reduction in MADRS defined as 25-49% reduction in MADRS score from baseline. Statistical analysis using score from baseline. Statistical analysis using SPSS for Windows, release 11.5, was by SPSS for Windows, release 11.5, was by univariate analysis of variance covaried for univariate analysis of variance covaried for baseline values. Fisher's exact test was used baseline values. Fisher's exact test was used for categorical data and the for categorical data and the exact proportion exact proportion test for treatment allocation guesses. test for treatment allocation guesses.
RESULTS RESULTS
Thirteen patients (7 women; mean age 48 Thirteen patients (7 women There was no significant difference between was no significant difference between groups in median duration of episode (acgroups in median duration of episode (active 14 months, range 3-60; sham 12 tive 14 months, range 3-60; sham 12 months, range 2-144); median number of months, range 2-144); median number of treatment trials (active 3, range 0-7; sham treatment trials (active 3, range 0-7; sham 3, range 0-12); treatment resistance (active 3, range 0-12); treatment resistance (active 85%; sham 75%); electroconvulsive treat-85%; sham 75%); electroconvulsive treatment in episode (active 31%; sham 38%); ment in episode (active 31%; sham 38%); and chronic ( and chronic (5 52 years) episode (active 2 years) episode (active 46%; sham 38%). All but 3 patients were 46%; sham 38%). All but 3 patients were taking antidepressants (active 92%; sham taking antidepressants (active 92%; sham 88%); venlafaxine 34%; selective serotonin 88%); venlafaxine 34%; selective serotonin reuptake inhibitors 24%; tricyclic antidereuptake inhibitors 24%; tricyclic antidepressants 14%; combinations were most pressants 14%; combinations were most often with lithium (31%), an atypical antioften with lithium (31%), an atypical antipsychotic (34%) or two antidepressants psychotic (34%) or two antidepressants (17%). More patients in the active group (17%). More patients in the active group were receiving venlafaxine (62 were receiving venlafaxine (62 v.
v. 13%; 13%; P P5 50.05), with a trend for the opposite 0.05), with a trend for the opposite for selective serotonin reuptake inhibitors for selective serotonin reuptake inhibitors (8 (8 v. v. 38%, 38%, P P5 50.1). 0.1). Three patients in the active group parThree patients in the active group partially responded at 4 weeks and received a tially responded at 4 weeks and received a further 2 weeks' treatment. Twenty-five cases further 2 weeks' treatment. Twenty-five cases were evaluable for efficacy; at treatment endwere evaluable for efficacy; at treatment endpoint the active group improved more than point the active group improved more than the sham group on primary outcomes the sham group on primary outcomes (MADRS effect size 0.86, HAD depression (MADRS effect size 0.86, HAD depression effect size 0.92), GAF and in number of reeffect size 0.92), GAF and in number of responders (Table 1) . At 12 weeks significant sponders (Table 1) . At 12 weeks significant benefit to the active treatment group on benefit to the active treatment group on self-rated HAD depression remained. self-rated HAD depression remained.
Two patients per group withdrew before Two patients per group withdrew before completing 2 weeks of treatment (active: scalp completing 2 weeks of treatment (active: scalp pain, unrelated finger infection; sham: selfpain, unrelated finger infection; sham: selfharm, treatment too stressful). Two patients harm, treatment too stressful). Two patients in the active group received 100% (reduced in the active group received 100% (reduced from 110%) from 110%) motor threshold stimulation motor threshold stimulation owing to initial scalp discomfort, but overall owing to initial scalp discomfort, but overall the treatment was well tolerated. Three partithe treatment was well tolerated. Three participants did not return for assessment at 12 cipants did not return for assessment at 12 5 3 3 5 3 3 ( 2 0 0 7 ) , 1 9 0 , 5 3 3^5 3 4 . d o i : 1 0 .11 9 2 / b j p . b p .1 0 6 . 0 2 8 0 1 9 ( 2 0 0 7 ) , 1 9 0 , 5 3 3^5 3 4 . d o i : 1 0 . 11 9 2 / b j p . b p . 1 0 6 . 0 2 8 0 1 9 
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DISCUSSION DISCUSSION
In this small study, fast left frontal rTMS In this small study, fast left frontal rTMS given three times a week for 4-6 weeks given three times a week for 4-6 weeks was effective in mainly treatment-resistant was effective in mainly treatment-resistant depression and tolerability was generally depression and tolerability was generally good. Hypomania following rTMS has been good. Hypomania following rTMS has been reported before (Dolberg reported before (Dolberg et al et al, 2001) , is con-, 2001), is consistent with rTMS having antidepressant sistent with rTMS having antidepressant properties and indicates the need to screen properties and indicates the need to screen for bipolarity. Seizures have occasionally for bipolarity. Seizures have occasionally occurred during fast rTMS stimulation occurred during fast rTMS stimulation (Wassermann, 1998); however, delayed seiz-(Wassermann, 1998); however, delayed seizure provocation has not been described, is ure provocation has not been described, is mechanistically implausible and rTMS causamechanistically implausible and rTMS causation in this case was thought very unlikely. tion in this case was thought very unlikely.
Meta . , 2006). Our study is limited by its small number Our study is limited by its small number of participants, relatively brief follow-up of participants, relatively brief follow-up and uncontrolled concomitant medication. and uncontrolled concomitant medication. Nevertheless, taken together with other Nevertheless, taken together with other recent studies, our findings suggest that fast recent studies, our findings suggest that fast left frontal rTMS warrants further evalualeft frontal rTMS warrants further evaluation as a clinically available treatment. A tion as a clinically available treatment. A clinically feasible protocol of three treatclinically feasible protocol of three treatments per week appears effective, provided ments per week appears effective, provided that sufficient stimulation strength and that sufficient stimulation strength and numbers of treatments are used. numbers of treatments are used. MADRS MADRS 27.7 (7.1) 27.7 (7.1) 23.4 (9.8) 23.4 (9.8) 21.9 (9.7) 21.9 (9.7) 21.5 (9.7) 21.5 (9.7) 26.7 (3.6) 26.7 (3.6) 15 (9.7)* 15 (9.7)* 14.0 (11.5) 14.0 (11.5) 16.0 (11.9) 16.0 (11.9) CGI-S CGI-S 4.1 (0.7) 4.1 (0.7) 4.0 (0.8) 4.0 (0.8) 3.7 (1.2) 3.7 (1.2) 3.7 (1.2) 3.7 (1.2) 3.7 (0.6) 3.7 (0.6) 3.0 (1.0) 3.0 (1.0) 3.0 (1.3) 3.0 (1.3) 3.0 (1.3) 3.0 (1.3)
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